Abiraterone-based HDAC inhibitor targets glioblastoma stemness and redox adaptation via filaggrin
Glioblastoma, the most aggressive primary brain cancer in adults, has long defeated the standard chemotherapeutic temozolomide through a frustrating combination ...
